Share
Chris Cleary
Restore Medical Ltd., a privately held medical device company focused on advancing innovative therapies for heart failure, has appointed former Medtronic executive Chris Cleary as Chairman of its Board of Directors.
The appointment marks a significant milestone as the company prepares to enter its next phase of clinical development and global growth.
Restore Medical is developing a proprietary, minimally invasive transcatheter therapy aimed at treating patients with heart failure with reduced ejection fraction (HFrEF), a condition with significant unmet clinical need worldwide. Following encouraging early clinical results, the company is now advancing toward expanded clinical studies, including an upcoming U.S. trial, while strengthening its leadership and governance to support long-term commercialization and international expansion.
Chris Cleary brings more than 30 years of senior leadership experience across global healthcare and medical technology sectors. He previously served as Senior Vice President of Corporate Development at Medtronic, where he played a pivotal role in shaping the company’s strategic growth agenda.
During his tenure, Cleary led numerous landmark mergers and acquisitions, most notably Medtronic’s US$50 billion acquisition of Covidien - one of the largest transactions in the history of the medical technology industry.
In addition to Covidien, Cleary oversaw multiple high-impact deals across key growth areas including structural heart, neuromodulation, and spine, helping scale innovative technologies into global platforms. His deep expertise in corporate strategy, M&A execution, and building high-growth medical technology businesses is expected to be instrumental as Restore Medical transitions from early clinical validation to broader clinical adoption.
As Chairman, Cleary will support Restore Medical’s leadership team in refining strategy, navigating regulatory pathways, and positioning the company for future partnerships and market entry, reinforcing its mission to improve outcomes for patients living with heart failure.
